english.prescrire.org > Spotlight > "Spotlight"
"Spotlight"

Negative post-marketing trials: often ignored

 Outlook  Accelerated or conditional marketing authorisation pathways are designed to speed up patient access to potential therapeutic advances. But when post­-marketing trials conducted to evaluate these drugs using clinical endpoints do not confirm the pre-authorisation trial results obtained using surrogate endpoints, drug regulatory agencies and the organisations responsible for cancer guidelines rarely take these negative results into account.
Full article available for download by subscribers

©Prescrire 1 December 2023

Source: "Negative post-marketing trials: often ignored" Prescrire Int 2023; 32 (254): 304-305. Subscribers only.

Enjoy full access to Prescrire International, and support independent information